AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery
Open accessThe DOI matches its Crossref record; 78 of the 82 references it cites were found in a registry or an index; 6 of the 66 sources its claims cite were checked for support.
Abstract
Introduction: The eye is an excellent target for gene therapy because of its anatomical features. Gene therapy to treat ocular disorders relies on efficient gene delivery and transgene expression in the target cells. The aim of this study was to compare the biodistribution and safety of two different AAV serotypes after intravitreal (IVT) and subretinal injections. Methods: AAV2 (1 × 1012 vg/mL) and AAV9 (5 × 1012 vg/mL) vectors expressing an enhanced green fluorescent protein (EGFP) and an AAV9-empty (6 × 1011 vg/mL) vector were injected intravitreally or subretinally into both eyes of adult C57Bl/OlaHsd mice. The biodistribution of the viral vectors in the eye and off-target tissues was studied using qPCR. GFP expression was studied from cryosections, and GFP transduction efficacy was verified using immunohistostaining for GFP. In addition, electroretinography (ERG) was used to assess the effect of vectors on retinal function. Results: In addition to the eyes, viral vector copies were found in distant off-target tissues such as the liver, especially after AAV9-EGFP IVT and subretinal injections. AAV9-EGFP injections showed more GFP expression throughout the retina compared to AAV2-EGFP. AAV2-EGFP IVT showed transgene expression mainly in the ganglion cell layer, whereas subretinal injection showed GFP expression in the retinal pigment epithelium. In addition, GFP was expressed at a moderate level in the liver after both injection routes of AAV9 and in parts of the brain after all injection groups except AAV9-empty. Lowered a- and b-amplitude values were seen in ERG in both scotopic and photopic experiments after AAV9-EGFP subretinal injection compared to all other groups. Discussion: This study shows that intraocular injection of AAV2 and AAV9 transduces retinal cells. Although the more efficient transduction of the retina, negative effect on the retinal function, and off-target transgene expression of AAV9 makes AAV2 a more suitable gene delivery vector to treat ocular disorders.
Overview
CoChat Summary
TL;DR
AAV9-EGFP transduced the mouse retina more efficiently than AAV2-EGFP after both intravitreal and subretinal injection, but AAV9 also produced more off-target expression and reduced retinal function after subretinal delivery. The authors conclude AAV2 is a more suitable vector for ocular gene therapy.
Key findings
- AAV9-EGFP IVT and subretinal injections transduced approximately 30%–40% of the retina; AAV2-EGFP IVT transduced approximately 10%, and AAV2-EGFP subretinal injection approximately 2%.
- AAV2-EGFP IVT mainly transduced the ganglion cell layer, whereas AAV2-EGFP subretinal injection mainly transduced the RPE; AAV9-EGFP transduced throughout the retina after both routes.
- Vector copies were found in distant tissues, especially the liver after AAV9-EGFP IVT and subretinal injections. GFP was expressed at a moderate level in the liver after both AAV9 routes and in parts of the brain after all groups except AAV9-empty.
- AAV9-EGFP subretinal injection lowered a- and b-wave amplitudes in scotopic and photopic ERG compared with other groups; scotopic a-wave p < 0.05 vs naive and p < 0.01 vs the rest, scotopic b-wave p < 0.05 vs naive and p < 0.01 vs the rest, and photopic b-wave p < 0.05 vs AAV9 IVT. It also caused retinal detachment and folding.
Methods
- AAV2-EGFP (1 × 10^12 vg/mL), AAV9-EGFP (5 × 10^12 vg/mL), and AAV9-empty (6 × 10^11 vg/mL) were injected intravitreally or subretinally into both eyes of adult C57Bl/OlaHsd mice; 2 µL was given per eye.
- Thirty-one male C57BL/6JOlaHsd mice aged 14–19 weeks were used; mice were euthanized 1 month after injection, and eyes, brain, lung, heart, liver, spleen, kidneys, testicles, lymph nodes, and quadriceps muscles were harvested.
- Biodistribution was assessed by qPCR for WPRE copies per microgram genomic DNA; GFP expression was assessed from cryosections and immunohistostaining; retinal function was assessed by scotopic and photopic ERG, with two-way ANOVA and Bonferroni correction (p < 0.05 significant).
Limitations
- The paper does not include a dedicated limitations section.
- Limitations evident from the text include the use of only male mice, a single 1-month post-injection timepoint, and a rodent model whose thinner inner limiting membrane differs from humans and larger animals.
- The text also notes that GFP immunogenicity/toxicity and the subretinal injection procedure itself may contribute to morphological changes, which could confound interpretation of safety and ERG results.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
6 Valid · 0 Not valid · 36 Not checked · 82 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In one clinical trial with patients who presented with pre-existing antibodies against AAV2, subretinal injection of AAV2-mediated gene therapy caused only four of 15 subjects to experience a significant increase of circulating anti-AAV2 antibodies in serum, suggesting a limited systemic response (Jacobson et al., 2012).”
§ AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery > 1 Introduction
What the sources say
- Partly supportedcites Jacobson et al., 2012 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a causen = 15- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, in the vitreous humor, the level of pre-existing antibodies against AAVs is lower than the levels in the serum (Lee et al., 2019).”
§ AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery > 1 Introduction
What the sources say
- Supportedcites Lee et al., 2019 source
The Abstract (Results) states 'NAb levels were much lower in the vitreous humor than in the serum regardless of serotype,' and the Discussion repeats it as a key finding ('the level of pre-existing NAbs in the vitreous humor was much lower than that in the serum, regardless of AAV serotype'). The Results section and Table 1 quantify it (AAV2 serum median 2673.0 vs vitreous 20.0; AAV5 171.0 vs 2.0; AAV8 10.5 vs 2.0; AAV9 92.0 vs 2.0; all P < 0.001). The only narrowing qualifier is that the source measures neutralizing antibodies in patients undergoing vitrectomy for vitreoretinal disease, which the citing sentence renders as 'antibodies'; this does not alter the attributed point. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This could implicate both rod- and cone-focused pathway dependency being compromised in this group because the a-wave originates from the photoreceptor level, and the b-wave is mainly composed of bipolar cell response (Brown, 1968; Stockton and Slaughter, 1989; Pugh et al., 1998).”
§ AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery > 4 Discussion
What the sources say
- Not checked yetcites Brown, 1968 source
- Supportedcites Stockton and Slaughter, 1989 source
The Discussion states that the ERG b-wave results from light-evoked depolarization of ON bipolar neurons. The paper also identifies the a-wave as a photoreceptor-related phenomenon (pp. 115–116). The proposed compromise of rod- and cone-focused pathways is the citing authors’ inference, not a finding attributed to this source. (LLM, conf=0.92)
- Not checked yetcites Pugh et al., 1998 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, GFP was expressed in the surrounding muscles, the ciliary body (CB), and the trabecular meshwork (TM).”
§ AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery > 3 Results > 3.1 AAV9-EGFP intraocular injection transduced the retina more efficiently than AAV2-EGFP injections
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, GFP was expressed at a moderate level in the liver after both injection routes of AAV9 and in parts of the brain after all injection groups except AAV9-empty.”
§ AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
72 more claims
Create a free account to see all 124 claims and to verify the 60 references still open.
- Probably not a substantial claim. 34
- It may state two separate claims as one. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“AAV vector delivery via intravitreal (IVT) injection is a minimally invasive procedure that offers the potential for broad inner retinal transduction, providing significant transgene expression in the ganglion cell layer (GCL) (10, 14–17), and in particular in retinal ganglion cells (RGCs) (17–20).”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery > 3 Results > 3.4 qPCR
“After subretinal injection, AAV2-EGFP vector copies were found at low levels in the liver and one gonad sample.”
§ AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery > 3 Results > 3.4 qPCR
“No vector copies were found in the brain, heart, lung, liver, kidney, or spleen.”
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490 · cited 2×
“Vector copies have been shown to be present in the liver, lung, heart, kidney, testes, brain, and muscle after intravenous injection of AAV9 (Zincarelli et al., 2008).”
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406 · cited 1×
“Due to static, dynamic, and metabolic barriers, delivery of drug and gene therapy to the back of the eye is challenging (Gaudana et al., 2010).”
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 1×
“AAV vectors have a broad tropism in different tissues; their use results in long-term expression of the transgene, and they have been shown to be less immunogenic than several other viral vectors (Zincarelli et al., 2008; Li and Samulski, 2020).”
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641 · cited 1×
“AAV2 has a tropism for smooth muscle, skeletal muscle, central nervous system, liver, and kidney, and AAV9 has a tropism for the liver, heart, brain, skeletal muscle, lungs, pancreas, and kidney (Verdera et al., 2020).”
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW
JAGER, R. D., AIELLO, L. P., PATEL, S. C., & CUNNINGHAM, E. T. (2004) · Retina · doi:10.1097/00006982-200410000-00002 · Cited by 572 · cited 1×
“…injections pose a burden for both the patient and the healthcare system and increase the risk of injection-related adverse events, including intraocular in fl ammation, hemorrhage, ocular hypertension, and cataract, although the overall risk of a severe adverse event is low (Jager et al., 2004).”
The electroretinogram: Its components and their origins
Brown, K. T. (1968) · Vision Research · doi:10.1016/0042-6989(68)90041-2 · Cited by 558 · cited 1×
“This could implicate both rod-and cone-focused pathway dependency being compromised in this group because the a-wave originates from the photoreceptor level, and the b-wave is mainly composed of bipolar cell response (Brown, 1968; Stockton and Slaughter, 1989; Pugh et al., 1998).”
Webvision: The Organization of the Retina and Visual System
Kolb, H., Fernández, E., & Nelson, R. (1995) · Cited by 544
B-wave of the electroretinogram. A reflection of ON bipolar cell activity
Stockton, R. A., & Slaughter, M. M. (1989) · The Journal of general physiology · doi:10.1085/jgp.93.1.101 · Cited by 446
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Inner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Cellular remodeling in mammalian retina: Results from studies of experimental retinal detachment
Fisher, S. K., Lewis, G. P., Linberg, K. A., & Verardo, M. R. (2005) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.10.004 · Cited by 298
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board (2018) · Ophthalmologica · doi:10.1159/000486145 · Cited by 297 · cited 1×
“Although invasive, IVT injection remains the most common delivery method of drugs and gene therapy to the posterior segment (Grzybowski et al., 2018).”
Viral vector‐based gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269 · cited 3×
“Ophthalmological diseases are the third most common indication in clinical trials (Zhao et al., 2022).”
InfluentialCukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268
AAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249 · cited 1×
“…retina related to subretinal injection (Fisher et al., 2005; Fernandez-Bueno et al., 2019), vector dose (Jacobson et al., 2006; Beltran et al., 2010; Xiong et al., 2019), promoter used (Beltran et al., 2010; Xiong et al., 2019), or the immunogenicity and toxicity of the GFP (Khabou et al., 2018).”
Mori, S., Wang, L., Takeuchi, T., & Kanda, T. (2004) · Virology · doi:10.1016/j.virol.2004.10.012 · Cited by 245 · cited 1×
“Studies have shown low levels of vector copies in distal organs, including the liver, brain, and spleen, after IVT of AAV2 (MacLachlan et al., 2011) and in the liver, spleen, kidney, muscle, lung, and heart after intravenous injection (Mori et al., 2004).”
Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey
Vandenberghe, L. H., Bell, P., Maguire, A. M., Cearley, C. N., Xiao, R., Calcedo, R., Wang, L., Castle, M. J., Maguire, A. C., Grant, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002103 · Cited by 242
Gene therapy clinical trials, where do we go? An overview
Arabi, F., Mansouri, V., & Ahmadbeigi, N. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113324 · Cited by 233
Jacobson, S. G., Acland, G. M., Aguirre, G. D., Aleman, T. S., Schwartz, S. B., Cideciyan, A. V., Zeiss, C. J., Komaromy, A. M., Kaushal, S., Roman, A. J., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.005 · Cited by 224
Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review
Butt, M., Zaman, M., Ahmad, A., Khan, R., Mallhi, T., Hasan, M., Khan, Y., Hafeez, S., Massoud, E., Rahman, M., et al. (2022) · Genes · doi:10.3390/genes13081370 · Cited by 210
Vitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189
(2008) · PubMed Central · Cited by 183
Preclinical safety evaluation of AAV2-sFLT01— a gene therapy for age-related macular degeneration
MacLachlan, T. K., Lukason, M., Collins, M., Munger, R., Isenberger, E., Rogers, C., Malatos, S., DuFresne, E., Morris, J., Calcedo, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.258 · Cited by 166
Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV
Dudus, L., Anand, V., Acland, G. M., Chen, S.-J., Wilson, J. M., Fisher, K. J., Maguire, A. M., & Bennett, J. (1999) · Vision Research · doi:10.1016/s0042-6989(98)00308-3 · Cited by 160
Axonal transport of adeno-associated viral vectors is serotype-dependent
Salegio, E. A., Samaranch, L., Kells, A. P., Mittermeyer, G., San Sebastian, W., Zhou, S., Beyer, J., Forsayeth, J., & Bankiewicz, K. S. (2013) · Gene Therapy · doi:10.1038/gt.2012.27 · Cited by 156
Hellström, M., Ruitenberg, M. J., Pollett, M. A., Ehlert, E. M. E., Twisk, J., Verhaagen, J., & Harvey, A. R. (2009) · Gene Therapy · doi:10.1038/gt.2008.178 · Cited by 142
Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis
Le Meur, G., Lebranchu, P., Billaud, F., Adjali, O., Schmitt, S., Bézieau, S., Péréon, Y., Valabregue, R., Ivan, C., Darmon, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.014 · Cited by 137
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
Drug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120 · cited 1×
“Plasmid DNA and small DNA and RNA molecules are nonpathogenic and unlikely to be immunogenic and mutagenic (Bordet and Behar-Cohen, 2019; Butt et al., 2022).”
Pugh, E. N., Falsini, B., & Lyubarsky, A. L. (1998) · Photostasis and Related Phenomena · doi:10.1007/978-1-4899-1549-8_7 · Cited by 117
AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis
Griffey, M., Macauley, S. L., Ogilvie, J. M., & Sands, M. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.018 · Cited by 115 · cited 2×
“In previous studies, vector sequences have been detected in the brain and optic nerve after AAV2 IVT injection in rats, dogs (Provost et al., 2005), mice (Griffey et al., 2005), and nonhuman primates (MacLachlan et al., 2011; Calkins et al., 2021).”
Retinal gene therapy: surgical vector delivery in the translation to clinical trials
Ochakovski, G. A., Bartz-Schmidt, K. U., & Fischer, M. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00174 · Cited by 110
Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., et al. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22473 · Cited by 108
Subretinal injection techniques for retinal disease: A review
Irigoyen, C., Amenabar Alonso, A., Sanchez-Molina, J., Rodríguez-Hidalgo, M., Lara-López, A., & Ruiz-Ederra, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164717 · Cited by 106
Pang, J.-J., Lauramore, A., Deng, W.-T., Li, Q., Doyle, T. J., Chiodo, V., Li, J., & Hauswirth, W. W. (2008) · Vision Research · doi:10.1016/j.visres.2007.08.009 · Cited by 97
AAV9 targets cone photoreceptors in the nonhuman primate retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053463 · Cited by 97
Beltran, W. A., Boye, S. L., Boye, S. E., Chiodo, V. A., Lewin, A. S., Hauswirth, W. W., & Aguirre, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.56 · Cited by 96 · cited 2×
“…retina related to subretinal injection (Fisher et al., 2005; Fernandez-Bueno et al., 2019), vector dose (Jacobson et al., 2006; Beltran et al., 2010; Xiong et al., 2019), promoter used (Beltran et al., 2010; Xiong et al., 2019), or the immunogenicity and toxicity of the GFP (Khabou et al., 2018).”
Dosage thresholds and influence of transgene cassette in adeno-associated virus–related toxicity
Khabou, H., Cordeau, C., Pacot, L., Fisson, S., & Dalkara, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.144 · Cited by 93
Provost, N., Le Meur, G., Weber, M., Mendes-Madeira, A., Podevin, G., Cherel, Y., Colle, M.-A., Deschamps, J.-Y., Moullier, P., & Rolling, F. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.022 · Cited by 87
Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations
Beltran, W. A., Cideciyan, A. V., Boye, S. E., Ye, G.-J., Iwabe, S., Dufour, V. L., Marinho, L. F., Swider, M., Kosyk, M. S., Sha, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.004 · Cited by 82 · cited 1×
“Promoter optimization has been shown to transduce targeted cells ef fi ciently (Beltran et al., 2017; Hanlon et al., 2017) and also has been shown to limit unwanted off-target cell transduction (Lu et al., 2016; Beltran et al., 2017; Hanlon et al., 2017).”
Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina
Boye, S. L., Alexander, J. J., Witherspoon, C. D., Boye, S. L., Peterson, J. J., Clark, M. E., Sandefer, K. J., Girkin, C. A., Hauswirth, W. W., & Gamlin, P. D. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.085 · Cited by 82
Advances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82 · cited 1×
“The eye is an excellent target for gene therapy because of its anatomical features (Petit et al., 2016).”
Lu, Q., Ganjawala, T. H., Ivanova, E., Cheng, J. G., Troilo, D., & Pan, Z.-H. (2016) · Gene Therapy · doi:10.1038/gt.2016.42 · Cited by 77
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration
Davis, J. L., Gregori, N. Z., MacLaren, R. E., & Lam, B. L. (2019) · Retina · doi:10.1097/iae.0000000000002609 · Cited by 72
Gene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63 · cited 1×
“The eye is relatively immune-privileged and easy to access, and blood – ocular barriers limit systemic biodistribution and side effects of the introduced genetic material (Moore et al., 2017).”
Systemic and local immune responses to intraocular AAV vector administration in non-human primates
Ail, D., Ren, D., Brazhnikova, E., Nouvel-Jaillard, C., Bertin, S., Mirashrafi, S. B., Fisson, S., & Dalkara, D. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.011 · Cited by 61
Han, I. C., Cheng, J. L., Burnight, E. R., Ralston, C. L., Fick, J. L., Thomsen, G. J., Tovar, E. F., Russell, S. R., Sohn, E. H., Mullins, R. F., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.043 · Cited by 60
Barker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
Optimization of AAV vectors to target persistent viral reservoirs
Colón-Thillet, R., Jerome, K. R., & Stone, D. (2021) · Virology Journal · doi:10.1186/s12985-021-01555-7 · Cited by 50 · cited 1×
“Differences in the tropism are determined by the AAV capsid, the primary attachment receptor, and the co-receptor speci fi city of each serotype (Colón-Thillet et al., 2021).”
Ocular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
Evaluation of AAV-DJ vector for retinal gene therapy
Katada, Y., Kobayashi, K., Tsubota, K., & Kurihara, T. (2019) · PeerJ · doi:10.7717/peerj.6317 · Cited by 46 · cited 1×
“Capsid modi fi cations have been shown to enhance transgene delivery to the outer retina after IVT (Petrs-Silva et al., 2009; Dalkara et al., 2013; Katada et al., 2019; Pavlou et al., 2021).”
Kalesnykas, G., Kokki, E., Alasaarela, L., Lesch, H. P., Tuulos, T., Kinnunen, K., Uusitalo, H., Airenne, K., & Yla-Herttuala, S. (2017) · Current Gene Therapy · doi:10.2174/1566523217666171003170348 · Cited by 43
Self-citationBiodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primates
Calkins, D. J., Yu-Wai-Man, P., Newman, N. J., Taiel, M., Singh, P., Chalmey, C., Rogue, A., Carelli, V., Ancian, P., & Sahel, J. A. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.013 · Cited by 37
A novel retinal ganglion cell promoter for utility in AAV vectors
Hanlon, K. S., Chadderton, N., Palfi, A., Blanco Fernandez, A., Humphries, P., Kenna, P. F., Millington-Ward, S., & Farrar, G. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00521 · Cited by 34
Teo, K. Y. C., Lee, S. Y., Barathi, A. V., Tun, S. B. B., Tan, L., & Constable, I. J. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.18-24333 · Cited by 33
Touchard, E., Benard, R., Bigot, K., Laffitte, J.-D., Buggage, R., Bordet, T., & Behar-Cohen, F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.013 · Cited by 32
Li, T., Sun, J., Min, J., Zhou, S., Zhu, X., Jia, H., & Sun, X. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.3096 · Cited by 31
Lee, S. H., Yang, J. Y., Madrakhimov, S. B., Park, H. Y., Park, K., & Park, T. K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.008 · Cited by 29
Lee, S., Kang, I. K., Kim, J. H., Jung, B. K., Park, K., Chang, H., Lee, J. Y., & Lee, H. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.2.14 · Cited by 27
Adeno-associated virus serotype-9 efficiently transduces the retinal outer plexiform layer.
Lei, B., Zhang, K., Yue, Y., Ghosh, A., & Duan, D. (2009) · PubMed Central · Cited by 27
Viral-vector-delivered anti-angiogenic therapies to the eye
Koponen, S., Kokki, E., Kinnunen, K., & Ylä-Herttuala, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020219 · Cited by 24
Self-citationKorpela, H., Lampela, J., Airaksinen, J., Järveläinen, N., Siimes, S., Valli, K., Nieminen, T., Turunen, M., Grönman, M., Saraste, A., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00322-9 · Cited by 22
Self-citationA Single Intravenous AAV9 Injection Mediates Bilateral Gene Transfer to the Adult Mouse Retina
Bemelmans, A., Duqué, S. I., Rivière, C., Astord, S., Desrosiers, M., Marais, T., Sahel, J., Voït, T., & Barkats, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061618 · Cited by 22 · cited 1×
“In addition, intravenous injection of AAV9-GFP via the tail vein has been shown to induce retinal (RPE, PR, ONL, OPL, INL, IPL, and GCL), choroidal, and optic nerve transduction in mice, indicating that AAV9 is able to cross the blood – retinal barrier (Bemelmans et al., 2013).”
Optimized Protocol for Accurate Titration of Adeno-Associated Virus Vectors
Suoranta, T., Laham-Karam, N., & Ylä‐Herttuala, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.318 · Cited by 21
Self-citationLee, S. H., Kim, Y.-S., Nah, S. K., Kim, H. J., Park, H. Y., Yang, J. Y., Park, K., & Park, T. K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.008 · Cited by 19
Fernandez‐Bueno, I., Alonso-Alonso, M. L., García-Gutiérrez, M.-T., & Diebold, Y. (2019) · PubMed Central · Cited by 9
Puranen, J., Koponen, S., Nieminen, T., Kanerva, I., Kokki, E., Toivanen, P., Urtti, A., Ylä-Herttuala, S., & Ruponen, M. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2022.109237 · Cited by 9
Self-citationSafety of Intravitreal Injection Guide
Watanabe, K., Uematsu, M., Mohamed, Y. H., et al. (2017) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126417728622 · Cited by 6
Research works printed but not linked: 1
- Perlman, 1995, The electroretinogram: Erg
Cited by
Hadi, M., Allela, O. Q. B., Jabari, M., Jasoor, A. M., Naderloo, O., Yasamineh, S., Gholizadeh, O., & Kalantari, L. (2024) · Virology Journal · doi:10.1186/s12985-024-02286-1 · Cited by 37
“Smooth muscle, skeletal muscle, the CNS, the liver, and the kidney are all targets of AAV2 tropism [39].”
BackgroundSeeing the Future: A Review of Ocular Therapy
Whalen, M., Akula, M., McNamee, S. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11020179 · Cited by 21
“Moderate transduction efficiency in the ONL [128]. at doses above 1 × 10 10 vg/eye [134].”
BackgroundBernardo‐Colón, A., Bighinati, A., Parween, S., Debnath, S., Piano, I., Adani, E., Corsi, F., Gargini, C., Vergara, M. N., Marigo, V., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00789-8 · Cited by 24
“We selected the adeno-associated virus serotype 2 (AAV2) due to its ef fi cacy in transducing retinal cells, making it well-suited for treating ocular disorders 46 .”
Replenishing IRAK-M expression in retinal pigment epithelium attenuates outer retinal degeneration
Liu, J., Copland, D. A., Clare, A. J., Gorski, M., Richards, B. T., Scott, L. M., Theodoropoulou, S., Greferath, U., Cox, K. H. M., Shi, G., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi4125 · Cited by 10
“In nonhuman primates and mice, subretinal injection of AAV2. cytomegalovirus (CMV) preferably transduces the RPE and, at higher doses, PRs ( 51 , 52 ).”
BackgroundOcular Delivery of Viral Vectors for Retinal and Choroidal Vascular Diseases: A Review
Agrawal, R., Oraskovich, S. V., Francis, P. J., & Schaffer, D. V. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.07.025 · Cited by 7
Metadata
- Authors
- Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S.
- Affiliations
- University of Eastern Finland (FI)
- Venue
- Frontiers in Drug Delivery
- Publisher
- Frontiers Media SA
- Published
- 2023-07-12
- Volume
- 3
- Pages
- 1148795-1148795
- ISSN
- 2674-0850 (ISSN-L)
- PMC
- PMC12363253
- OpenAlex
- W4384071789
- Cited by
- 21
- References
- 82
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 4
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Drug Delivery (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Mary och Georg C. Ehrnrooths Stiftelse
- Silmäsäätiö
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- AAV2, AAV9, adeno-associated virus serotypes, ocular gene therapy, intravitreal injection, subretinal injection, retinal transduction, transgene expression, tissue distribution, retinal function, electroretinogram, retinal pigment epithelium, retinal ganglion cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.